The impact of phosphodiesterase inhibition on neurobehavioral outcomes in preclinical models of traumatic and non-traumatic spinal cord injury: a systematic review.

Frontiers Media SA https://doi.org/10.3389/fmed.2023.1237219 Front Med (Lausanne) 2023-09-08T12:03:46Z 2023-09-08T12:03:46Z 2023 2023-06-09 2023-09-08T12:03:45Z

Peer reviewed: True
Acknowledgements: We gratefully acknowledge support from the Cambridge NIHR Brain Injury MedTech Cooperative.
STUDY DESIGN: Systematic review. OBJECTIVE: The objective of this study was to evaluate the impact of phosphodiesterase (PDE) inhibitors on neurobehavioral outcomes in preclinical models of traumatic and non-traumatic spinal cord injury (SCI). METHODS: A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and was registered with PROSPERO (CRD42019150639). Searches were performed in MEDLINE and Embase. Studies were included if they evaluated the impact of PDE inhibitors on neurobehavioral outcomes in preclinical models of traumatic or non-traumatic SCI. Data were extracted from relevant studies, including sample characteristics, injury model, and neurobehavioral assessment and outcomes. Risk of bias was assessed using the SYRCLE checklist. RESULTS: The search yielded a total of 1,679 studies, of which 22 met inclusion criteria. Sample sizes ranged from 11 to 144 animals. PDE inhibitors used include rolipram (n = 16), cilostazol (n = 4), roflumilast (n = 1), and PDE4-I (n = 1). The injury models used were traumatic SCI (n = 18), spinal cord ischemia (n = 3), and degenerative cervical myelopathy (n = 1). The most commonly assessed outcome measures were Basso, Beattie, Bresnahan (BBB) locomotor score (n = 13), and grid walking (n = 7). Of the 22 papers that met the final inclusion criteria, 12 showed a significant improvement in neurobehavioral outcomes following the use of PDE inhibitors, four papers had mixed findings and six found PDE inhibitors to be ineffective in improving neurobehavioral recovery following an SCI. Notably, these findings were broadly consistent across different PDE inhibitors and spinal cord injury models. CONCLUSION: In preclinical models of traumatic and non-traumatic SCI, the administration of PDE inhibitors appeared to be associated with statistically significant improvements in neurobehavioral outcomes in a majority of included studies. However, the evidence was

neurobehavioral outcomes; phosphodiesterase inhibitor; preclinical model; spinal cord; spinal cord injury; Article

Open access content. Open access content

application/pdf
application/zip
application/octet-stream
text/xml
English
English

HS1 oai:www.repository.cam.ac.uk:1810/356900
1488037315

UNIV OF CAMBRIDGE
From OAIster®, provided by the OCLC Cooperative.

edsoai.on1488037315